Citadel Advisors
DAWN

Citadel Advisors’s Day One Biopharmaceuticals DAWN Stock Holding History

Citadel Advisors’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,359,613
Closed -$19.2M – 13178
2025
Q4 		$12.7M Buy
1,359,613
+696,400
+105% +$5.82M ﹤0.01% 2931
2025
Q3 		$4.68M Sell
663,213
-40,431
-6% -$278K ﹤0.01% 4486
2025
Q2 		$4.57M Sell
703,644
-635,374
-47% -$4.37M ﹤0.01% 4271
2025
Q1 		$10.6M Buy
1,339,018
+727,705
+119% +$7.84M ﹤0.01% 2775
2024
Q4 		$7.75M Buy
611,313
+127,052
+26% +$1.77M ﹤0.01% 3303
2024
Q3 		$6.75M Buy
484,261
+114,653
+31% +$1.64M ﹤0.01% 3476
2024
Q2 		$5.09M Buy
369,608
+322,343
+682% +$4.72M ﹤0.01% 3721
2024
Q1 		$781K Buy
47,265
+39,998
+550% +$599K ﹤0.01% 7444
2023
Q4 		$106K Buy
7,267
+513
+8% +$6.22K ﹤0.01% 10858
2023
Q3 		$82.9K Sell
6,754
-765,402
-99% -$9.98M ﹤0.01% 11125
2023
Q2 		$9.22M Buy
772,156
+378,072
+96% +$4.94M ﹤0.01% 2783
2023
Q1 		$5.27M Buy
394,084
+387,213
+5,635% +$7.56M ﹤0.01% 3718
2022
Q4 		$148K Sell
6,871
-41,077
-86% -$843K ﹤0.01% 10629
2022
Q3 		$961K Sell
47,948
-11,856
-20% -$252K ﹤0.01% 7075
2022
Q2 		$1.07M Sell
59,804
-51,932
-46% -$536K ﹤0.01% 6867
2022
Q1 		$1.11M Buy
+111,736
New +$1.48M ﹤0.01% 7466

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Citadel Advisors's DAWN Position: Q1 2026 in Review

Citadel Advisors sold out of Day One Biopharmaceuticals (DAWN) in Q1 2026, closing a stake of 1,359,613 shares — an estimated $19.2M sold.

Citadel Advisors first reported a position in DAWN in Q1 2022 and held it in 16 quarters. The position peaked at $12.7M in Q4 2025. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • Citadel Advisors reported no remaining Day One Biopharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 1,359,613 Day One Biopharmaceuticals shares in Q1 2026, an estimated $19.2M.
  • Citadel Advisors first reported a position in Day One Biopharmaceuticals in Q1 2022 and held it in 16 quarters.
  • Citadel Advisors's Day One Biopharmaceuticals position peaked at $12.7M in Q4 2025.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.